Actively Recruiting
Cardiac Dysfunction in Patients with Fatty Liver Disease
Led by Post Graduate Institute of Medical Education and Research, Chandigarh · Updated on 2025-01-29
150
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre. The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD. In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease, there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease, hypertensive heart disease, cirrhotic cardiomyopathy, which are contributors to overall cardiovascular risk of mortality.
CONDITIONS
Official Title
Cardiac Dysfunction in Patients with Fatty Liver Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 65 years
- Diagnosis of metabolic dysfunction-associated steatotic liver disease confirmed by histology, clinical, laboratory, non-invasive tests, ultrasound, or vibration controlled transient elastography (VCTE)
You will not qualify if you...
- Age over 65 years
- Chronic renal disease
- Pregnancy or peripartum cardiomyopathy
- Hypertension
- Valvular heart disease
- Sick sinus syndrome or pacemaker
- Cardiac rhythm disorders
- Hypothyroidism
- Hyperthyroidism
- Portal vein thrombosis
- Transjugular intrahepatic portosystemic shunt (TIPS) insertion
- Hepatocellular carcinoma
- Anemia with hemoglobin less than 8 gm/dl in females or less than 9 gm/dl in males at assessment time
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Dr. Madhumita Premkumar
Chandigarh, Chandigarh, India, 160012
Actively Recruiting
Research Team
M
Madhumita Premkumar
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here